Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop targets Mite-Related eyelid inflammation in phase 2 trial

NCT ID NCT06720896

Disease control Sponsor: Aperta Biosciences, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new eye drop (APT-001, containing spinosad 1.8%) for blepharitis, a condition causing red, irritated eyelids often linked to tiny mites. About 100 people with symptoms will receive either the active drop or a placebo. The goal is to see if the treatment clears eyelid debris and redness safely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic blepharitis. * At least 6 years of age. * Eyelid collarette count (minimum score 2). * Willing and able to follow all instructions and attend all study visits. * Able to avoid prohibited medication for the duration of the study. * Patients can willingly provide consent or have a legal authorized representative provide consent on the informed consent (IC) Form. Exclusion Criteria: * Women with confirmed pregnancies. * Utilizing any current medical therapy for the eye. * History of allergic reaction to spinosad or any formulation component. * Patients using eyelid hygiene or other treatment(s) for blepharitis within 14 days of screening. * History of ocular surgery within the past 1 year. * Presence of other ocular diseases that may affect study outcomes (Corneal Dystrophies, Salzmanns disease, Severe dry eye, Keratoconus, Glaucoma filtering blebs). * Use of investigational drug, chronic glaucoma medications, steroid. * Uncontrolled systemic disease. * Acute or chronic illness that would confound study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blepharitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

blepharitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blepharitis

Contacts and locations

Locations

  • Dr. Rudy Gutierrez Diaz Sede Central

    Guatemala City, Guatemala

  • EyeScan, Imágenes Diagnósticas Oculares, S. A.

    Guatemala City, Guatemala

More trials for these conditions

Other studies related to the condition(s) this trial covers.